Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia
- Resource Type
- Article
- Source
- In
Value in Health Regional Issues December 2021 26:182-190 - Subject
- Language
- ISSN
- 2212-1099